Serono Sues Cell Genesys Over TKT Gene Activation Patent

Law360, New York (September 1, 2004, 12:00 AM EDT) -- A subsidiary of Switzerland’s Serono has sued Transkaryotic Therapies (TKT) licensee Cell Genesys, alleging that gene activation technology used in the production of TKT’s biological drugs infringes a U.S. patent.

Serono’s subsidiary, Applied Research Systems, filed the amended complaint in the U.S. District Court for the District of Massachusetts, claiming infringement of its U.S. patent No. 5,272,071.

In the original complaint, Serono appealed a U.S. Patent and Trademark Office decision that 34 of the claims of the '071 patent are invalid.

Serono and Cell Genesys were...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.